Diagnostic biomarkers in multiple sclerosis

Expert Opinion on Medical Diagnostics

Volumn 1, Issue 2, 2007, Pages 225-233

  Kuenz, Bettina ^a   Deisenhammer, Florian ^a   Berger, Thomas ^a   Reindl, Markus ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

antimyelin antibodies; aquaporin 4 antibodies; biomarkers; cerebrospinal fluid; MRI; multiple sclerosis

Indexed keywords

EID: 78650106918     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.1.2.225     Document Type: Review

References (97)

1. NOSEWORTHY JH, LUCCHINETTI C, RODRIGUEZ M, WEINSHENKER BG: Multiple sclerosis. N. Engl. J. Med. (2000) 343 (13): 938-952.
2. O RIORDAN JI, THOMPSON AJ, KINGSLEY DP et al. : The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 121 (Part 3): 495-503. (Pubitemid 28116346)
3. JACOBS LD, KABA SE, MILLER CM, PRIORE RL, BROWNSCHEIDLE CM: Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann. Neurol. (1997) 41 (3): 392-398. (Pubitemid 27114051)
4. BREX PA, CICCARELLI O, ORIORDAN JI et al. : A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. (2002) 346 (3): 158-164. (Pubitemid 34438881)
5. WEINSHENKER BG, BASS B, RICE GP et al. : The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain (1989) 112 (Part 1): 133-146. (Pubitemid 19056478)
6. LUBLIN FD, REINGOLD SC: Defi ning the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology (1996) 46 (4): 907-911.
7. VUKUSIC S, CONFAVREUX C: Primary and secondary progressive multiple sclerosis. J. Neurol. Sci. (2003) 206 (2): 153-155. (Pubitemid 36143720)
8. MCDONALD WI: Relapse, remission, and progression in multiple sclerosis. N. Engl. J. Med. (2000) 343 (20): 1486-1487.
9. WINGERCHUK DM, WEINSHENKER BG: Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology (2003) 60 (5): 848-853. (Pubitemid 36297372)
10. CREE BA, GOODIN DS, HAUSER SL: Neuromyelitis optica. Semin. Neurol. (2002) 22 (2): 105-122. (Pubitemid 35425276)
11. TENEMBAUM S, CHITNIS T, NESS J, HAHN JS: Acute disseminated encephalomyelitis. Neurology (2007) 68 (16 Suppl. 2): S23-S36. (Pubitemid 46626003)
12. KORTE JH, BOM EP, VOS LD, BREUER TJ, WONDERGEM JH: Balo concentric sclerosis: MR diagnosis. AJNR Am. J. Neuroradiol. (1994) 15 (7): 1284-1285. (Pubitemid 24257855)
13. LASSMANN H, BRUCK W, LUCCHINETTI CF: The immunopathology of multiple sclerosis: an overview. Brain Pathol. (2007) 17 (2): 210-218. (Pubitemid 46466140)
14. LASSMANN H, BRUCK W, LUCCHINETTI C: Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. (2001) 7 (3): 115-121. (Pubitemid 32201673)
15. BABBE H, ROERS A, WAISMAN A et al. : Clonal expansions of CD8( +) T cells dominate the T cell infi ltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. (2000) 192 (3): 393-404. (Pubitemid 30629164)
16. KUTZELNIGG A, LUCCHINETTI CF, STADELMANN C et al. : Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 128 (Part 11): 2705-2712. (Pubitemid 41552953)
17. LUCCHINETTI C, BRUCK W, PARISI J et al. : Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. (2000) 47 (6): 707-717. (Pubitemid 30390191)
18. GRANIERI E, CASETTA I, TOLA MR, FERRANTE P: Multiple sclerosis: infectious hypothesis. Neurol. Sci. (2001) 22 (2): 179-185. (Pubitemid 33771288)
19. DYMENT DA, EBERS GC, SADOVNICK AD: Genetics of multiple sclerosis. Lancet Neurol. (2004) 3 (2): 104-110. (Pubitemid 38121313)
20. COO H, ARONSON KJ: A systematic review of several potential non-genetic risk factors for multiple sclerosis. Neuroepidemiology (2004) 23 (1-2): 1-12. (Pubitemid 38142267)
21. SOSPEDRA M, MARTIN R: Immunology of multiple sclerosis. Annu. Rev. Immunol. (2005) 23 : 683-747. (Pubitemid 40563183)
22. HAINES JL, BRADFORD Y, GARCIA ME et al. : Multiple susceptibility loci for multiple sclerosis. Hum. Mol. Genet. (2002) 11 (19): 2251-2256.
23. MCDONALD WI, COMPSTON A, EDAN G et al. : Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. (2001) 50 (1): 121-127.
24. KLEINSCHMIDT-DEMASTERS BK, TYLER KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon â-1a for multiple sclerosis. N. Engl. J. Med. (2005) 353 (4): 369-374. (Pubitemid 41132341)
25. BERGER T, DEISENHAMMER F: Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis. N. Engl. J. Med. (2005) 353 (16): 1744-1746; author reply 1744-1746. (Pubitemid 41464718)
26. POLMAN CH, REINGOLD SC, EDAN G et al. : Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria . Ann. Neurol. (2005) 58 (6): 840-846. (Pubitemid 41746873)
27. MILLER DH: Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx (2004) 1 (2): 284-294. (Pubitemid 46591886)
28. MCFARLAND HF, BARKHOF F, ANTEL J, MILLER DH: The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult. Scler. (2002) 8 (1): 40-51. (Pubitemid 34193027)
29. GROSSMAN RI, GONZALEZ-SCARANO F, ATLAS SW, GALETTA S, SILBERBERG DH: Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology (1986) 161 (3): 721-725. (Pubitemid 17200424)
30. THORPE JW, KIDD D, MOSELEY IF et al. : Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology (1996) 46 (2): 373-378. (Pubitemid 26081316)
31. THOMPSON AJ, KERMODE AG, WICKS D et al. : Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann. Neurol. (1991) 29 (1): 53-62.
32. PANITCH H, MILLER A, PATY D, WEINSHENKER B: Interferon â-1b in secondary progressive MS: results from a 3-year controlled study. Neurology (2004) 63 (10): 1788-1795. (Pubitemid 39532370)
33. MILLER DH, SOON D, FERNANDO KT et al. : MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 68 (17): 1390-1401. (Pubitemid 46659091)
34. JACOBS LD, BECK RW, SIMON JH et al. : Intramuscular interferon â-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group. N. Engl. J. Med. (2000) 343 (13): 898-904.
35. COMI G, FILIPPI M, WOLINSKY JS: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate study group. Ann. Neurol. (2001) 49 (3): 290-297. (Pubitemid 32202781)
36. RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF INTERFERON â -1A IN RELAPSING/REMITTING MULTIPLE SCLEROSIS: PRISMS (Prevention of relapses and disability by interferon â-1a subcutaneously in multiple sclerosis) study group. Lancet (1998) 352 (9139): 1498-1504.
37. Interferon â-1B in the treatment of multiple sclerosis: fi nal outcome of the randomized controlled trial. The IFNB multiple sclerosis study group and the university of British Columbia MS/MRI analysis group. Neurology 1995: 45: 7: 1277-1285.
38. KAPPOS L, MOERI D, RADUE EW et al. : Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI meta-analysis group. Lancet (1999) 353 (9157): 964-969. (Pubitemid 29132605)
39. KHALEELI Z, SASTRE-GARRIGA J, CICCARELLI O, MILLER DH, THOMPSON AJ: Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over one year in early primary progressive MS. J. Neurol. Neurosurg. Psychiatry (2007).
40. KALKERS NF, BERGERS E, CASTELIJNS JA et al. : Optimizing the association between disability and biological markers in MS. Neurology (2001) 57 (7): 1253-1258. (Pubitemid 32947385)
41. FREEDMAN MS, THOMPSON EJ, DEISENHAMMER F et al. : Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch. Neurol. (2005) 62 (6): 865-870. (Pubitemid 40973448)
42. KABAT EA, MOORE DH, LANDOW H: An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J. Clin. Invest. (1942) 21 (5): 571-577.
43. REIBER H: Cerebrospinal fluid - physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult. Scler. (1998) 4 (3): 99-107. (Pubitemid 28410032)
44. LINK H, HUANG YM: Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J. Neuroimmunol. (2006) 180 (1-2): 17-28. (Pubitemid 44692326)
45. HANSEN K, CRUZ M, LINK H: Oligoclonal Borrelia burgdorferi-specific IgG antibodies in cerebrospinal fluid in Lyme neuroborreliosis. J. Infect. Dis. (1990) 161 (6): 1194-1202. (Pubitemid 20177880)
46. LUCCHINETTI CF, MANDLER RN, MCGAVERN D et al. : A role for humoral mechanisms in the pathogenesis of Devics neuromyelitis optica. Brain (2002) 125 (Part 7):1450-1461. (Pubitemid 34755161)
47. VILLAR LM, MASJUAN J, GONZALEZ-PORQUE P et al. : Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann. Neurol. (2003) 53 (2): 222-226. (Pubitemid 36164004)
48. VILLAR LM, MASJUAN J, GONZALEZ-PORQUE P et al. : Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology (2002) 59 (4): 555-559. (Pubitemid 34919989)
49. SHARIEF MK, THOMPSON EJ: Intrathecal immunoglobulin M synthesis in multiple sclerosis. Relationship with clinical and cerebrospinal fluid parameters. Brain (1991) 114 (Part 1A): 181-195.
50. SHARIEF MK, KEIR G, THOMPSON EJ: Intrathecal synthesis of IgM in neurological diseases: a comparison between detection of oligoclonal bands and quantitative estimation. J. Neurol. Sci. (1990) 96 (2-3): 131-142. (Pubitemid 20187693)
51. SERAFINI B, ROSICARELLI B, MAGLIOZZI R, STIGLIANO E, ALOISI F: Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. (2004) 14 (2): 164-174. (Pubitemid 38656388)
52. OWENS GP, RITCHIE AM, BURGOON MP et al. : Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J. Immunol. (2003) 171 (5): 2725-2733. (Pubitemid 37025586)
53. OWENS GP, KRAUS H, BURGOON MP et al. : Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann. Neurol. (1998) 43 (2): 236-243. (Pubitemid 28110126)
54. COLOMBO M, DONO M, GAZZOLA P et al. : Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J. Immunol. (2000) 164 (5): 2782-2789. (Pubitemid 30115513)
55. BARANZINI SE, JEONG MC, BUTUNOI C et al. : B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J. Immunol. (1999) 163 (9): 5133-5144. (Pubitemid 29501283)
56. CEPOK S, JACOBSEN M, SCHOCK S et al. : Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain (2001) 124 (Part 11): 2169-2176. (Pubitemid 33055362)
57. CORCIONE A, CASAZZA S, FERRETTI E et al. : Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA (2004) 101 (30): 11064-11069. (Pubitemid 38989584)
58. CEPOK S, VON GELDERN G, GRUMMEL V et al. : Accumulation of class switched IgD-IgM-memory B cells in the cerebrospinal fluid during neuroinfl ammation. J. Neuroimmunol. (2006) 180 (1-2): 33-39. (Pubitemid 44692322)
59. CEPOK S, ROSCHE B, GRUMMEL V et al. : Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain (2005) 128 (Part 7): 1667-1676. (Pubitemid 41373685)
60. WINGERCHUK DM, HOGANCAMP WF, OBRIEN PC, WEINSHENKER BG: The clinical course of neuromyelitis optica (Devics syndrome). Neurology (1999) 53 (5): 1107-1114. (Pubitemid 29442132)
61. LENNON VA, WINGERCHUK DM, KRYZER TJ et al. : A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 364 (9451): 2106-2112. (Pubitemid 39626806)
62. LENNON VA, KRYZER TJ, PITTOCK SJ, VERKMAN AS, HINSON SR: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. (2005) 202 (4): 473-477. (Pubitemid 41186945)
63. ROEMER SF, PARISI JE, LENNON VA et al. : Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 130 (Part 5): 1194-1205. (Pubitemid 47355941)
64. MISU T, FUJIHARA K, KAKITA A et al. : Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain (2007) 130 (Part 5): 1224-1234. (Pubitemid 47355951)
65. ISHIZU T, OSOEGAWA M, MEI FJ et al. : Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain (2005) 128 (Part 5): 988-1002. (Pubitemid 40675455)
66. WEINSHENKER BG, WINGERCHUK DM, PITTOCK SJ, LUCCHINETTI CF, LENNON VA: NMO-IgG: a specific biomarker for neuromyelitis optica. Dis. Markers (2006) 22 (4): 197-206. (Pubitemid 44763273)
67. WINGERCHUK DM, LENNON VA, PITTOCK SJ, LUCCHINETTI CF, WEINSHENKER BG: Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 66 (10): 1485-1489. (Pubitemid 43958540)
68. TAKAHASHI T, FUJIHARA K, NAKASHIMA I et al. : Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain (2007) 130 (Part 5): 1235-1243. (Pubitemid 47355956)
69. PAUL F, JARIUS S, AKTAS O et al. : Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. (2007) 4 (4): E133 .
70. MATSUOKA T, MATSUSHITA T, KAWANO Y et al. : Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain (2007) 130 (Part 5): 1206-1223. (Pubitemid 47355945)
71. JARIUS S, FRANCIOTTA D, BERGAMASCHI R et al. : NMO-IgG in the diagnosis of neuromyelitis optica. Neurology (2007) 68 (13): 1076-1077. (Pubitemid 46569147)
72. WEINSHENKER BG, WINGERCHUK DM, VUKUSIC S et al. : Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann. Neurol. (2006) 59 (3): 566-569. (Pubitemid 43358081)
73. KEEGAN M, PINEDA AA, MCCLELLAND RL et al. : Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology (2002) 58 (1): 143-146.
74. CREE BA, LAMB S, MORGAN K et al. : An open label study of the effects of rituximab in neuromyelitis optica. Neurology (2005) 64 (7): 1270-1272.
75. REINDL M, KHALIL M, BERGER T: Antibodies as biological markers for pathophysiological processes in MS. J. Neuroimmunol. (2006) 180 (1-2): 50-62. (Pubitemid 44692320)
76. LUCCHINETTI CF, BRUCK W, RODRIGUEZ M, LASSMANN H: Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. (1996) 6 (3): 259-274. (Pubitemid 26246382)
77. BRUCK W, NEUBERT K, BERGER T, WEBER JR: Clinical, radiological, immunological and pathological findings in infl ammatory CNS demyelination - possible markers for an antibody-mediated process. Mult. Scler. (2001) 7 (3): 173-177. (Pubitemid 32651817)
78. KEEGAN M, KONIG F, MCCLELLAND R et al. : Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 366 (9485): 579-582. (Pubitemid 41140333)
79. BRUNNER C, LASSMANN H, WAEHNELDT TV, MATTHIEU JM, LININGTON C: Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′ ?′ ,3′? -cyclic nucleotide 3′?-phosphodiesterase in the CNS of adult rats. J. Neurochem. (1989) 52 (1): 296-304. (Pubitemid 19023382)
80. KERLERO DE ROSBO N, HONEGGER P, LASSMANN H, MATTHIEU JM: Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. J. Neurochem. (1990) 55 (2): 583-587.
81. LININGTON C, BRADL M, LASSMANN H, BRUNNER C, VASS K: Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. (1988) 130 (3): 443-454. (Pubitemid 18091372)
82. GENAIN CP, CANNELLA B, HAUSER SL, RAINE CS: Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. (1999) 5 (2): 170-175. (Pubitemid 29068523)
83. ZHOU D, SRIVASTAVA R, NESSLER S et al. : Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc. Natl. Acad. Sci. USA (2006) 103 (50): 19057-19062. (Pubitemid 350002827)
84. LALIVE PH, MENGE T, DELARASSE C et al. : Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early infl ammation in multiple sclerosis. Proc. Natl. Acad. Sci. USA (2006) 103 (7): 2280-2285. (Pubitemid 43271661)
85. GAERTNER S, DE GRAAF KL, GREVE B, WEISSERT R: Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology (2004) 63 (12): 2381-2383. (Pubitemid 40024355)
86. O CONNOR KC, MCLAUGHLIN KA, DE JAGER PL et al. : Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat. Med. (2007) 13 (2): 211-217.
87. PITTOCK SJ, REINDL M, ACHENBACH S et al. : Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult. Scler. (2007) 13 (1): 7-16. (Pubitemid 46152756)
88. TOMASSINI V, DE GIGLIO L, REINDL M et al. : Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult. Scler. (2007) (In Press).
89. BERGER T, RUBNER P, SCHAUTZER F et al. : Antimyelin antibodies as a predictor of clinically defi nite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. (2003) 349 (2): 139-145. (Pubitemid 36818783)
90. RAUER S, EULER B, REINDL M, BERGER T: Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J. Neurol. Neurosurg. Psychiatry (2006) 77 (6): 739-742. (Pubitemid 43837200)
91. KUHLE J, LINDBERG RL, REGENITER A et al. : Antimyelin antibodies in clinically isolated syndromes correlate with infl ammation in MRI and CSF. J. Neurol. (2007) 254 (2): 160-168. (Pubitemid 46356047)
92. PELAYO R, TINTORE M, MONTALBAN X et al. : Antimyelin antibodies with no progression to multiple sclerosis. N. Engl. J. Med. (2007) 356 (4): 426-428. (Pubitemid 46148809)
93. LIM ET, BERGER T, REINDL M et al. : Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult. Scler. (2005) 11 (4): 492-494. (Pubitemid 40984247)
94. KUHLE J, POHL C, MEHLING M et al. : Lack of association between antimyelin antibodies and progression to multiple sclerosis. N. Engl. J. Med. (2007) 356 (4): 371-378. (Pubitemid 46148779)
95. BIELEKOVA B, MARTIN R: Development of biomarkers in multiple sclerosis. Brain (2004) 127 (Part 7): 1463-1478. (Pubitemid 38899400)
96. TRABOULSEE AL, LI DK: The role of MRI in the diagnosis of multiple sclerosis. Adv. Neurol. (2006) 98 : 125-146.
97. MAYRINGER I, DEISENHAMMER F: Quality rating of quantitative and qualitative IgG synthesis in liquor. J. Lab. Med. (2005) 29 (6): 429-433. (Pubitemid 43004900)